Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 36Irinotecan 27Specimen Handling 23Biopsy 20Chemotherapy, Adjuvant 17Capecitabine 14Cetuximab 13Magnetic Resonance Spectroscopy 12Folfox protocol 12Bevacizumab 12Neoadjuvant Therapy 10sargramostim 6aldesleukin 6Melphalan 6Radiotherapy 5Floxuridine 5Cyclophosphamide 5dehydroftorafur 4X-Rays 4Nivolumab 4Interferon-alpha 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Celecoxib 4fludarabine 3durvalumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Colorectal Neoplasms × rofecoxib × Clear all
NCT00031863 2013-08-02

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡